Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
The company showcased three core programs developed through this platform
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
Subscribe To Our Newsletter & Stay Updated
